The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.4, representing a -12.11% change from its previous close.
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.41, signifying a -13.01% move from its prior day's close.
Humacyte, Inc. (HUMA) closed at $0.41 in the latest trading session, marking a +1.28% move from the prior day.
In the most recent trading session, Humacyte, Inc. (HUMA) closed at $0.4, indicating a -6.5% shift from the previous trading day.
Detailed price information for Humacyte Inc (HUMA-Q) from The Globe and Mail including charting and trades.
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.48, signifying a -4.26% move from its prior day's close.
DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing uni...
Humacyte, Inc. (HUMA) reached $0.59 at the closing of the latest trading day, reflecting a +2.23% change compared to its last close.
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on September 16, 2026, at 11:00am Eastern Time. Management will also b
– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all established quality specifications throughout the 36-month dating period – DURHAM, N.C., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that the U.S. Food and Drug Administration (FDA) has a
Humacyte (HUMA) said Wednesday the US Food and Drug Administration has authorized an extension of th
– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 – – Supplemental BLA will be supported by results from three Phase 3 studies of ATEV, including results from V012 dialysis access study in women – – The V012 dialysis access study found that women who received Humacyte's ATEV experienced an average of three more months without a dialysis catheter than women who received AV fistula, the current standard of care – DU
Humacyte (HUMA) said Monday it plans to file in November a supplemental biologics license applicatio
This is the newest page. Registered accounts read further back.